At ATTD 2026, Dexcom (Nasdaq:DXCM) outlined a range of ways in which its continuous glucose monitors (CGMs) benefit people ...

Let's consider why this healthcare specialist could be an under-the-radar winner of the GLP-1 boom. Will AI create the ...

Diabetes technology innovators gathered last week for the Advanced Technologies and Treatments for Diabetes Conference (ATTD ...

DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the CGM market. A strong third-quarter 2025 performance and a series of favorable coverage decisions ...

Dexcom's Apple Watch app will be ready to go when the device launches in April, the company told the Wall Street Journal. The app, which will not need to seek pre-market approval from the FDA thanks ...

DexCom's devices are important to its customers' health. The company still has significant whitespace in its market. Despite potential obstacles, the stock is still attractive. Even so, the ...

DexCom, Inc. DXCM is well positioned for growth in the coming quarters, supported by the significant potential of the continuous glucose monitoring (CGM) market. A strong preliminary fourth-quarter ...